plant recipients is frequently implicated as an important cause for allograft dysfunction. 1 The demonstrated antibody prevalence in the worldwide population to BKV is more than than 80%. 2, 3 Primary infection is usually acquired during infancy and, following its course, the virus establishes latency, principally in the urogenital tract. 4 Viral reactivation accompanied by urine shedding may occur under different immunologic deficiencies (hematological malignancies, congenital immunodeficiency, Wiskott-Aldrich syndrome), but mostly affected by its effect are transplant recipients (kidney and bone marrow). 5 The reason, which makes these patients susceptible to BKV reactivation, is possibly due to the interaction of multiple factors (determinants of the host, transplanted organ, and the virus itself), but the use of new, highly potent immunosuppressive drugs is mostly accentuated. [4] [5] [6] [7] In the mid 1990s, the introduction of thirdgeneration immunosuppressive drug regimens into the routine management of renal allograft recipients was followed by the reemergence of BK polyomavirus-associated nephropathy (BKAN). 8 From a rare condition, it gained enormous clinical and social interest by its significant incidence in recent years with documented prevalence, usually between 1% and 5% among kidney-transplant recipients. Fortunately, these medications reduced the acute rejection rates but obviously created a permissive environment for prolonged viral replication and development of BKAN. [9] [10] [11] [12] The condition is connected not only with BK viruria/viremia but also with severe allograft dysfunction and graft-loss ranging from 10% to 100%. 4, 5, 13 The diagnosis and screening for BKV reactivation are challenging procedures. On one hand, asymptomatic BKV replication may occur in 10% to 68% of renal transplant patients. 4, 14 On the other, currently there are no standard means of diagnosis, except kidney biopsy demonstrating interstitial nephritis with characteristic viral inclusion bodies. 11 Therefore, the specimen tested and the applied diagnostic method should be carefully selected. Recently, a combination of different noninvasive diagnostic markers was used to define viral replication and patients at risk of developing BKAN: the presence of urinary decoy cells, PCR on urine/plasma, and electron microscopy. 6 Routine post-transplant screening for BK viruria/viremia prior to the occurrence of the nephritis and reduction of the immunosuppressive therapy or including antivirals (cidofovir/leflunomide) in suspected cases has dramatically changed the outcome of BKAN, although many subjects with BKAN may experience graft failure. Nevertheless, the combination of early detection, prompt diagnosis, and the appropriate reduction in immunosuppressive therapy has been associated with a better prognosis. 4, 7, 15, 16 To date, there is no information on the frequency of BKV urine shedding/viremia and the related clinical consequences among Bulgarian renal-allograft subjects. Our objective was to evaluate the BKV replication pattern by using a diagnostic procedure introduced by us for the first time in our country. At the same time, we tried to identify which cases of graft dysfunction might be attributed to BKV reactivation. Finally, we tried to examine the viral reactivation among related recipient pairs prior to transplantation to determine if this could be an indication to the clinicians for the future management of these individuals.
Materials and Methods

Subjects and Specimen Collection
The investigation included a group of 50 kidney-transplant recipients (103 urines, 6 blood samples, 2 allograft necropsies). Eight donor-recipient pairs prior to transplantation (16 urines, 16 blood samples) and a control group of 30 non-transplant subjects (30 urines) with varying degrees of kidney dysfunction were also examined. Samples were collected randomly during the regular attendance of the patients at 2 different clinics: the Clinic of Urology and Transplantation and the Clinic of Nephrology and Transplantations (Medical University Hospital Alexandrovska, Sofia, Bulgaria). Approval of the study was obtained from the independent Ethics committee of both medical institutions. Age, race, gender, type of donor (deceased/living), immunosuppressive regimens, and cytomegalovirus (CMV) reactivation of the transplant recipients were also examined ( Table 1) .
Urine and blood, being the samples of interest, were collected serially where possible. Twenty to 50-mL of fresh voided first or second morning urine were collected in sterile containers (Biologix, USA) supplied with 5-mL absolute alcohol (Merck, Germany) preventing the unwanted development of Methods: For the first time in Bulgaria, we tried to perform investigations on BKV reactivation on a selected group of kidney transplant patients. By the use of surrogate diagnostic markersurine cytology and PCR on urine/plasma-we tried to evaluate their BKV reactivation and also in related recipient pairs. Sequence analysis was also applied in order to relate the viral genotype to the unfavorable prognosis, where observed.
Results:
The high incidence of viruria among allograft recipients (n=42/50, 84%) was linked occasionally to BKV disease, only in n=2/50 (4%) patients, presumptive BK-associated nephropathy (BKAN). BKAN genotypes analyzed by sequencing belonged to one genotype, which is frequently observed. BKV reactivation prior to transplantation in related transplant pairs was 25% (n=2/8) in the recipients who had viruria and viremia at the same time.
bacterial flora. 17 Blood was placed in vacutainers (Becton Dickinson, USA) containing EDTA as an anticoagulant.
Preliminary Urine Preparation and Cytological Studies
To obtain urothelial cells for cytological examination, the semi-automated Bales method was applied. 18 It consisted of the following steps: centrifugation of the voided urine at slow speed (3,000 rpm), removing the supernatant, and adding to the separated sediment 3 to 5 mL of 2% polyethylene glycol with 70% ethanol for better deposition of the cells. Following another centrifugation at the same speed, the reagents were removed, and a suspension of the pelleted sediment was made. Twenty to 50 μL was spread on a glass slide, air-dried, and fixed in absolute alcohol.
The prepared smears were stained by the use a Cytocolor kit (Merck, Germany) according to the manufacturer's protocol. The slides were embedded in Canada balsam (Fluka, Germany) and observed for decoy cells with a Carl Zeiss light microscope. Decoy cells were identified by their typical ground-glass intranuclear inclusions on the urine smears and their number was counted per 10 high-power fields. A cytological evaluation of concurrent adenovirus, herpes simplex, or cytomegalovirus infection in any of the patients was also made.
Blood Preparation
Freshly collected peripheral blood was initially left at 4°C for approximately half an hour until natural deposition of the cellular components at the bottom of the tube occured. The result was stratification of the obtained blood into clearly visible plasma and lower layer of forming elements. The plasma was then carefully removed and kept frozen at -70°C prior to DNA preparation if not simultaneously proceeded.
The remaining blood was processed for lymphocyte separation. This was performed by the use of the ficoll-containing density gradient reagent Lymphoflot (Biotest, Germany). In general, 2 mL volume/volume Hanks diluted blood were laid over an equal quantity of Lymphoflot and, for the further operations, the manufacturer's instructions were followed. After centrifugation at 2,500 rpm, the lymphocyte-enriched fraction was presented as an opalescent ring between the adjacent layers of plasma and the Lymphoflot-captivated red blood cells. Following its removal, the lymphocytes were suspended in 500 μL Hanks solution, pelleted at slow centrifugation (700 rpm) and kept at -70°C until DNA preparation.
DNA Preparation and Polymerase Chain Reaction
The extraction of DNA was performed by in-house modifications of the phenol/chloroform/iso-amyl (Invitrogen, USA) method in respect of the tested material (urine, plasma). DNA was precipitated by absolute ethanol and 3M sodium acetate, pelleted and rehydrated with 30 to 50 μL ultrapure water. Its concentration was measured spectrophotometrically in a hundredfold dilution (Eppendorf, Biospectrofotometer). Only samples with a satisfactory DNA amount were used in the amplification reactions. All the extraction procedures were held along with the proper extraction controls.
Polymerase chain reaction (PCR) for the BK virus detection was performed using specific primers for VP1 genomic region (327-1/327-2) 19 and in-house developed and optimized pair named Bk-1/Bk-2 in a qualitative reaction. In-house primer sets were derived from the nucleotide sequence of the N terminus of the BK viral T antigen (BK strain Dun, accession number V01108). 20 To ensure their specificity, all the reactions for primer optimization were run with the appropriate positive BKV DNA. BKV-specific primers and their features are described in Table 2 .
The amplification reactions were held in 50 μL volume with 10x reaction buffer, 1.5 mM magnesium chloride (ABgene), 200 µM from each of the 4 nucleotides (USB), and 1.25 U thermostable Taq polymerase (5U/μL, Invitrogen). A total of 5 μL (approximately 0.5 μg) extracted DNA and 600 nM of each primer were also added to the mixture. The amplification ramp included an initial step at 94°C for 5 min followed by a 3-step cycle consisting of 94°C for 30 s and extension at 72°C for 1 min. The annealing was for 30 s and the its temperature varied in respect to the used primers ( Table 1) . Aliquotes (25 μL) of each PCR product were run on 2% agarose gel stained with ethidium bromide for 80 min at 100 V (room temperature) along with 100 bp DNA MW ladder (Invitrogen). Suitability of DNA for analysis was checked by amplification of 110 bp fragment of the β-globin gene, and all assays included positive and negative controls. Sequencing of the Amplified BKV VP1 PCR Products In order to determine if variability of the viral genotype was influencing the course and development of BKAN, urine PCR amplicons of the patients with diagnosed disease were sequenced. Two PCR products corresponding to the VP1 region flanked by the primer pair 327-1/327-2 were examined. DNA sequencing was performed by automatic DNA sequencer (ABI Prism Big Dye Terminator, version 1.1) following manufacturer specifications. The sequenced products were compared with the reference strains and BKV clones from renal transplant patients available at the Genebank. Sequence analysis was performed with ClustalW program at the EMBL-EBM Web site using default parameters (www.ebi.ac.uk).
Statistical Analysis
Statistical analysis was completed using the Pearson criteria, with a value of 0.05 considered as the threshold of significance. Data between the study groups and variables was compared with one-way analysis of variance-ANOVA. The statistical calculations and the estimation of frequencies were carried out using the statistical software package SPSS 12.0.
Results
Outcome of BKV Reactivation Among Renal-Allograft Patients
The first group of results was connected with the investigations on BKV urine/plasma prevalence among renal-allograft recipients. A total of 103 urines/6 serial plasma samples taken randomly from 50 kidney recipients at time intervals after transplantation ranging from 1-2 months to 8 years were tested from March 2006 to July 2007. Patient records were examined for any registered complications after the procedure.
All the immunosuppressive therapy varied but generally was grouped into 2 categories: for subjects with a post-transplantation period of over 1 year, and a single regimen of cyclosporine A (n=19, 38%). Information was not obtained of their initial combination. The maintenance immediately after transplantation was in all cases a triple combination of prednisone, mycophenolate mofetic, and cyclosporine A (n=31, 62% of all cases). No tacrolimus therapy was available in the country. The other existing variations were connected both with the combination scheme and the applied dose of the medications. Cytomegalovirus reactivation as measured by the presence of CMV IgM antibodies was documented in 14 patietns (28%) but was successfully treated by intravenous application of Ganciclovir.
Polymerase chain reaction assessment on urine samples revealed that a large proportion (84%, n=42) of the kidney allograft recipients were shedding BKV ( Figure 1) . All of the positive urine samples were detected within a post-transplantation period of 1 year (median, 2 months). BKV viruria was observed to be influenced by the application of triple maintenance therapy including mycophenolate mofetil (P=0.01). Second specimens tested serially in equal intervals of a median 2 months after the first positive samples were also PCR-positive. The rest of 8 negative (16%) patients were normally living transplant recipients with a maintenance regimen of cyclosporine A. Significant variation was not determined in viruria in respect of the donor (living/cadaveric), age, gender, concomitant CMV reactivation, or the clinical manifest. On the other hand, there was clinical significance in viruria of the kidney allograft patients (P=0.01) when compared with the control group (26.7%). Sensitivity of both used primer sets appeared to be similar (data not shown).
During the study, decoy cells were identified in 30% (n=15) of the examined subjects who were PCR-positive. The inclusionbearing cells were easily identified in the cytological smears. They were larger than the normal urothelial cells and had nuclei of several types: opaque ground glass appearance or with remaining thin nuclear border chromatin ( Figure 2) . The cytological examination did not reveal suspicious data of concurrent CMV, HSV, or adenovirus cytopathology.
Two (n=2/50, 4%) of the viruric patients displayed rapid kidney deterioration in the month following transplantation. As there were no positive diagnostic markers of reactivated CMV infection or signs of immune rejection, regular monitoring at every month of the post-transplantation period for BKV reactivation was undertaken. Surrogate markers for BKAN diagnosis-cytology and PCR on urine/plasma were applied. At the end of the first month after transplantation, they were identified as BKV urine excretors as judged by the decoy cells and the positive urine PCR. The first plasma samples were negative. Subsequent urine and plasma tests in the following 3 months revealed massive viruria accompanied by viremia. The levels of sera creatinine were rising and reached maximal value of 994 μmol/L (range 44.2 to 133.6 μmol/L, clinical records). Medication consisted of 40 mg/daily methyl-prednisone, 300 mg/daily cyclosprine A, Azathioprine 2 mg/kg/daily, and Mycophenil phenolate 720 mg/daily. These patients were diagnosed as having possible BKVassociated nephritis (possible BKAN) by the help of the surrogate diagnostic tools listed previously. Their viruria preceded the viremic state, which strengthened the hypothesis. Subsequently, kidney necropsy material testing by PCR for BKV DNA was positive in both cases. The performed sequence studies on them indicated that the both BKV amplification products belonged to the subtype I.
BKV Reactivation Among Recipient Pairs
The second group of results is connected with BKV viruria/ viremia reactivation pattern in 8 donor-transplant living pairs prior to renal transplantation. Some of their characteristics taken from clinical records and BKV PCR are listed in Table 3 .
All of the donors were related to the recipients. No one showed BKV-associated viruria or viremia when examined by PCR (no BKV reactivation). The mean age of the allograft acceptors was 33.2 and they were diagnosed as having chronic renal dysfunction, a basic motive for their transplantation. Two of them (25%) showed viruria combined simultaneously with viremia.
Control Group
A control group of 30 non-transplant patients with renal diseases was also included. Their mean age was 47.9, and the group comprised 8 males (26.7%) and 22 females (73.3%).
Clinical records of the patients were taken into consideration for classifying the chronic renal diseases (3 types): pyelonephritis, glomerulonephritis, and renal insufficiency. They were not subjected to treatment with immunosuppressive drugs. Urine PCR was positive in 8 individuals (26.7%) with 10% (3/30) positive cytology. Some of the control group's characteristics are stated in Table 4 .
Discussion
BK virus reactivation and associated nephritis are growing problems in the field of renal transplantation. The exact cause of the increasing appearance of these conditions is still unclear, but it is often linked to the immunodeficiency induced by the applied immunosuppressive therapy. Clinical manifestations may vary from an asymptomatic state of viruria/viremia and nephritis to clinically renal dysfunction and allograft rejection. 15, 21 Our survey included 50 renal-transplant patients, 42 of whom (84%) were excreting BKV in their urine as judged by PCR and in 30% (n=15) decoy cells were found. According to the literature, among kidney allograft recipients silent BKV replication may range from 10% to 68% but not all of them go on to develop nephropathy. 4, 22, 23 Most tested individuals were obviously symptomless excretors because, with the exception of the mentioned 2 cases of possible BKAN, no BKV-associated complications were observed. Practically, a BK viruria may occur as a common event following renal transplantation with the onset usually within the first 3 months. 24 This may explain partly our slightly higher rate of BKV PCR urine detection, as the main proportion of subjects was tested within a year (median 2 months) after transplantation. Another reason may be sought in the immunologic state of these patients. The applied maintenance therapeutic scheme comprised 3 immunosuppressive medications and always contained mycophenolate mofetil, a new immunosuppressive drug. Except immunosuppressants used to treat rejection, age-induced change of the cellular immunity (mean age, 41.75) may also act as a cofactor for viral reactivation. 25, 26 But, in fact, higher rates of viruria were observed in patients receiving a triple-drug regimen (P=0.01). Nevertheless, PCR detection of BKV in urine most likely means viral replication. 27 When compared with the control group (26.7% PCR positivity, 10% decoy cell shedding, P=0.01), the general conclusion that can be made is that the whole procedure of renaltransplantation itself is a predisposing factor for BKV reactivation.
Obviously not a single reason, but multifactorial origin of the increased urinary shedding may be regarded. On the other hand, we did not find any viruria variance in respect of other determinants (gender, type of the donor [living/deceased]) of the subjects concomitant CMV reactivation, which is also in accordance with other available data. 28 Two patients (4%) of the examined group rapidly deteriorated during the first month after kidney transplantation. They were tested by all available markers for BK replication (possible BKAN), urine decoy cells, and PCR on urine/plasma. In the first month, the marked urine shedding of BKV (decoy cells >15 microscopic slide, positive urine PCR) did not coincide with viremia (negative PCR on plasma), but the following plasma samples became positive at the second month. Although the third paired (third month) samples were also positive for BK sequences, these 2 patients experienced irreversible graft failure. In these subjects, viruria preceded viremia, and this was the guiding approach for establishing the possible diagnosis. The presence of a circulating virus is associated with active nephropathy because the virions enter the circulation through peritubular capillaries following tubular damage. 29 That is why, in adult renal-allograft recipients, PCR on plasma (signifying active viral replication) has proven to be a sensitive and specific test for diagnosing BKV nephropathy. 27 Thus, BK viruria in renal-allograft recipients may be associated with viremia, and both markers clinically related to nephropathy that may lead to allograft rejection. 30 The performed genomic studies did not suggest that the detected genotype plays a contributory role to the BKAN development. Both tested samples were classified as subtype 1, which is most frequently found in the human population. 19, 31, 32 This implies that possibly multiple host features are determinants of whether or not a particular patient will develop BKV-mediated injury of the kidney. 32 Combination of our available surrogate tests specified the BKAN diagnosis. Signs of CMV reactivation and cellular-induced graft rejection had not been documented in their clinical records. Necropsy material, which was available for molecular investigation after the explantation, showed to be BKV-positive. Nevertheless, a noninvasive assay, which can guide the evaluation of BKAN, would be of invaluable clinical benefit. BKV PCR on urine and plasma combined with the search of decoy cells is useful in identifying renal recipients with concurrent BKAN. The negative PCR makes the diagnosis of BKAN highly unlikely. 33 Besides, it is possible to treat BKAN successfully at its early stages. 34 We believe that the introduced noninvasive diagnostic scheme for periodic assessment of urine cytology and urine and plasma PCR can serve not only for monitoring BKAN 35, 36 but also for diagnostic and prognostic purposes.
We tried to investigate BKV reactivation among recipient pairs prior to transplantation. The selected group consisted of 16 (8/8) paired donor-recipient patients, and plasma and urine were screened by PCR and urine cytology. No BKV signs of viruria/ viremia were observed among the donors, whereas 2 of 8 (25%) of the recipients who were diagnosed as having chronic renal insufficiency showed viremia and viruria with shedding of decoy cells. Reactivation can be observed in patients with progressive kidney diseases, 37 but what the impact will be for the recipient after the transplantation remains elusive. As different determinants for the development of BKAN are proposed, this also might be considered as a possible risk factor for BK-induced kidney disease after the transplantation and may attract the clinician's attention.
Our study contained a relatively small group of patients and available samples, but it shows the virologic pattern among kidney recipients in this part of the world. A positive impact of the investigation is the molecular and cytological base for further diagnostic and clinical improvements in the transplant centers of Bulgaria, where up to now there is no such information. Our general aim was to introduce a noninvasive diagnostic approach in patients suspicious for development of graft dysfunction. We think that the routine screening for the presence of decoy cells and urine/ plasma PCR is suitable for this purpose. Nevertheless, more studies are needed to assess the impact of BKV replication, disease, and factors for reactivation on kidney-allograft recipients. LM 
